Cisplatin and Gemcitabine
Phase 3Small molecule
Cisplatin and Gemcitabine is one of 54 small molecule programs targeting Nasopharyngeal Cancer. It is currently in Phase 3.
2
Indications
4
Total Trials
2
Active Trials
53
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
96 competitors in Triple-Negative Breast Cancer
#DrugCompanyPhaseTrials
1Taxol
TevaPhase 3
Keytruda
Merck & Co.Phase 3
Abraxane
Bristol-Myers SquibbPhase 3
Trodelvy
GileadPhase 3
Tecentriq
RochePhase 3
Halaven
EisaiPhase 3
Paraplatin
AAvyxa
Phase 3
Gemzar
Johnson & JohnsonPhase 3
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Imfinzi
AstraZenecaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Nasopharyngeal Cancer1 trial
Intrahepatic Cholangiocarcinoma1 trial
Triple-Negative Breast Cancer1 trial
Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard Chemotherapy
Not yet recruiting·—·Phase 2/3·NCT06268327·30 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Cisplatin and Gemcitabine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details